Mayne Pharma Group (ASX:MYX) FFO


ASX:MYX Mayne Pharma Group Ltd ASX:MYX
51 GF Score
Price A$2.57
GF Value A$5.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group FFO?

FFO (Funds from operations) only applies to REITs.

ASX:MYX
51GF Score
Mayne Pharma Group Ltd ASX:MYX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for ASX:MYX:

  • FFO:
  • GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MAYNF:USA
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score

Get the complete analysis for ASX:MYX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.57
Price
A$5.31
GF Value